ADTRALZA DIN 02521288
Status: Marketed
Holder: LEO PHARMA INC
Available to quote
Health Canada record
| Active ingredient(s) | TRALOKINUMAB 150 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | D11AH07 TRALOKINUMAB |
|---|
| Original market date | 17-Mar-2022 |
|---|
| Current status date | 17-Mar-2022 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
LEO Pharma Inc — licence 100195, currently licensed, last inspection rating C (2026-05-27).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TRALOKINUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02540193 | ADTRALZA | LEO PHARMA INC | Solution | TRALOKINUMAB 300 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 26843 | 2021-10-13 | New Drug Submission (NDS) | |
Request a quote for ADTRALZA
How to read a Canadian DIN record